Stockreport

New Data at ASTRO 2024 Shows Castle Biosciences' DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed ...

Castle Biosciences, Inc. - Common stock  (CSTL) 
Last castle biosciences, inc. - common stock earnings: 3/10 04:05 pm Check Earnings Report
PDF cutaneous squamous cell carcinoma (SCC) tumors were further stratified into distinct groups of those with more or less favorable survival by the DecisionDx-SCC test, inc [Read more]